Neurocrine Biosciences (NBIX) Stock Price, News & Analysis

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 6 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NBIX shares.
View NBIX analyst ratings or view top-rated stocks.

22 Wall Street analysts have issued 12 month price targets for Neurocrine Biosciences' shares. Their NBIX share price targets range from $100.00 to $165.00. On average, they predict the company's stock price to reach $139.67 in the next twelve months. This suggests a possible upside of 5.4% from the stock's current price.
View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts.

Neurocrine Biosciences' stock was trading at $131.76 at the beginning of 2024. Since then, NBIX shares have increased by 0.6% and is now trading at $132.54.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our NBIX earnings forecast.

Neurocrine Biosciences will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings data on Wednesday, February, 7th. The company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.31. The firm had revenue of $515.20 million for the quarter, compared to analysts' expectations of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a trailing twelve-month return on equity of 12.85%. The business's revenue for the quarter was up 25.0% compared to the same quarter last year. During the same period last year, the company posted $0.88 EPS.

ETFs with the largest weight of Neurocrine Biosciences (NASDAQ:NBIX) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Goldman Sachs Future Health Care Equity ETF (GDOC), Virtus LifeSci Biotech Products ETF (BBP), Invesco Bloomberg Pricing Power ETF (DEF), VictoryShares Nasdaq Next 50 ETF (QQQN) and American Century STOXX U.S. Quality Growth ETF (QGRO).

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).

Neurocrine Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.51%), Sumitomo Mitsui Trust Holdings Inc. (0.25%), Los Angeles Capital Management LLC (0.25%), Portman Square Capital LLP (0.00%), State of Michigan Retirement System (0.02%) and Sendero Wealth Management LLC (0.02%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, George J Morrow, Ingrid Delaet, Jude Onyia, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Leslie V Norwalk, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends.

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.